Skip to main content
SpringerLink
Log in

Effect of cetuximab in recurrent and refractory squamous cell carcinoma of the head and neck (SCCHN): a case report

  • Day-to-Day Practice
  • Published:
Targeted Oncology Aims and scope Submit manuscript

Abstract

The epidermal growth factor receptor (EGFR) is frequently overexpressed in squamous cell carcinoma of head and neck (SCCHN). Different strategies to target the activated EGFR have reached the clinic. Cetuximab is a monoclonal antibody that selectively binds to the extracellular domain of the EGFR on the tumor cell, thereby inhibiting receptor-associated tyrosine kinase activation. Two randomized phase III clinical trials have recently demonstrated that cetuximab increases the activity of radiotherapy in the treatment of locally advanced SCCHN and of platinum-based chemotherapy in the treatment of metastatic SCCHN. Here we report the clinical case of a long-lasting complete response in a 57-year-old male, who was a current smoker and had a history of alcohol abuse, affected by recurrent locally advanced SCCHN after failure of radiotherapy and of platinum-based chemotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ferlay J, Bray F, Pisani et al (2004) GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide. IARC Cancer-base no. 5, version 2.0 IARC, Lyon

  2. Forestiere A, Koch W, Trotti A et al (2001) Head and Neck. N Engl J Med 345:1890–1990

    Article  Google Scholar 

  3. Khuri FR, Shin DM, Glisson BS et al (2000) Treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck: current status and future directions. Semin Oncol 27:25–33

    PubMed  CAS  Google Scholar 

  4. Pignon JP, Bourhis J, Domenge C et al (2000) Chemotherapy added to locoregional treatment for head and neck squamous cell carcinoma: three meta-analysis of updated individual data. Lancet 355:949–955

    PubMed  CAS  Google Scholar 

  5. Garden AS, Asper JA, Morrison WH et al (2004) Is concurrent chemoradiation the treatment of choice for all patients with stage III or IV head and neck carcinoma? Cancer 100:1171–1178

    Article  PubMed  Google Scholar 

  6. Bourhis J, Overgaard J, Audry H et al (2006) Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 368:843–854

    Article  PubMed  Google Scholar 

  7. Budach W, Hehr T, Budach V et al (2006) A meta-analysis of hyperfractionated and accelerated and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck. BMC Cancer 6:839

    Article  CAS  Google Scholar 

  8. Brizel DM, Albers ME, Fisher SR et al (1998) Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 338:1798–1804

    Article  PubMed  CAS  Google Scholar 

  9. Domengue C, Hill C, Lefebre JL et al (2000) Randomized trial of neoadjuvant chemotherapy in oropharingeal carcinoma. French Groupe d’Etude des Tumeurs de la Tète et du Cou (GETTEC). Br J Cancer 83:1594–1598

    Article  Google Scholar 

  10. Zorat Pl, Paccagnella A, Cavaniglia G et al (2004) Randomized phase III trial of neoadjuvant chemotherapy in head and neck cancer: a ten year follow-up. J Natl Cancer Inst 96:1714–1717

    Article  PubMed  CAS  Google Scholar 

  11. Hitt R, Grau J, Lopez-Pousa A et al (2005) Phase II/III trial of induction chemotherapy(ICT) with cisplatin/5-fluorouracil (PF) versus docetaxel (T) plus PF (TPF) followed by chemoradiotherapy (CRT) versus CRT for unresectable locally advanced head and neck cancer (LAHNC). Proc Am Ass Clin Oncol 519s (abstract 5578)

  12. Murphy B, Li Y, Cella D et al (2001) Phase III study comparing cisplatin (C) and 5-fluorouracil (F) versus cisplatin and paclitaxel (T) in metastatic/recurrent head and neck cancer (MHNC). Proc Am Soc Clin Oncol 19:224a (abstract 894)

    Google Scholar 

  13. Hynes NE, Lane HA (2005) ERBB receptors and cancer: the complexity of target inhibitors. Nat Rev Cancer 5:341–354

    Article  PubMed  CAS  Google Scholar 

  14. Rubin Grandis J, Melhem MF, Gooding WE et al (1998) Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 90:824–832

    Article  PubMed  CAS  Google Scholar 

  15. Grandis JR (2006) Prognostic biomarkers in head and neck cancer. Clin Cancer Res 12:5005–5006

    Article  PubMed  CAS  Google Scholar 

  16. Ang KK, Berkey BA, Tu X et al (2002) Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62:7350–7356

    PubMed  CAS  Google Scholar 

  17. Temam S, Kawaguchi H, El-Naggai AK et al (2007) Epidermal growth factor receptor copy number alteration correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol 25:2164–2170

    Article  PubMed  CAS  Google Scholar 

  18. Bonner JA, Harari PM, Giralt J et al (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567–578

    Article  PubMed  CAS  Google Scholar 

  19. Cunan D, Giral J, Harari PM et al (2007) Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J Clin Oncol 25:2192–2197

    Google Scholar 

  20. Herbst RS, Arquette M, Shin DM et al (2005) Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 23:5578–5587

    Article  PubMed  CAS  Google Scholar 

  21. Baselga J, Trigo JM, Bourhis J et al (2005) Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinumrefractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 23:5568–5577

    Article  PubMed  CAS  Google Scholar 

  22. Burtness B, Goldwasser MA, Flood W et al (2005) Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 23:8646–8654

    Article  PubMed  Google Scholar 

  23. Vermoken JB, Mesia R, Vega E et al (2007). Cetuximab extends survival of patients or recurrent or metastatic SCCHN when added to first line platinum- based therapy results of a randomized phase III (EXTREME ) study. 2007 ASCO Annual Meeting: abstract 6091

  24. Vermorken JB, Trigo J, Hitt R et al (2007) Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum. J Clin Oncol 25:2171–2177

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Medical Oncology, Department of Clinical and Experimental Medicine and Surgery F. Magrassi and A. Lanzara, Second University of Naples School of Medicine, Via S. Panini 5, 80131, Naples, Italy

    Clorinda Schettino, Maria Anna Bareschino, Katia Monaco, Michele Orditura, Ferdinando De Vita & Fortunato Ciardiello

Authors
  1. Clorinda Schettino
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maria Anna Bareschino
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Katia Monaco
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michele Orditura
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ferdinando De Vita
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Fortunato Ciardiello
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fortunato Ciardiello.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schettino, C., Bareschino, M.A., Monaco, K. et al. Effect of cetuximab in recurrent and refractory squamous cell carcinoma of the head and neck (SCCHN): a case report. Targ Oncol 2, 253–257 (2007). https://doi.org/10.1007/s11523-007-0061-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11523-007-0061-6

Keywords

Search

Navigation